IGC Pharma (IGC) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed IGC Pharma (IGC) over the past year, gaining 63.9% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -99.4% for KTTA. IGC Pharma is the larger company by market cap ($19.6 million vs $17.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IGC | KTTA |
|---|---|---|
| Share price | $0.168 | $0.4787 |
| Market cap | $19.60M | $17.59M |
| 1-day change | -8.70% | -0.48% |
| YTD return | -40.00% | -62.89% |
| 1-year return | -47.50% | +63.94% |
| 5-year return | -87.65% | -99.40% |
| EPS (TTM) | $-0.07 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.27M | — |
| Revenue growth (YoY) | -5.50% | — |
| Net income (latest FY) | $-7.12M | $-20.43M |
| Gross margin | 48.70% | — |
| Operating margin | -585.84% | — |
| Net margin | -560.35% | — |
| 52-week high | $0.36 | $2.06 |
| 52-week low | $0.08 | $0.32 |
| Distance from 52-week high | -53.33% | -76.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +3471.43% | +526.70% |
| Average volume | 615.25K | 705.64K |
| Shares outstanding | 116.69M | 36.75M |
| Employees | 70 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed IGC by 111.4 percentage points over the past year.
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
IGC vs KTTA FAQ
Which is bigger, IGC Pharma or Pasithea Therapeutics?
IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $17.59M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, IGC or KTTA?
KTTA returned +63.94% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.
Are IGC Pharma and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.